ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1348

Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs

Aimara García-Studer1, Fernando Ortiz-Márquez1, Paula Borregón-Garrido1, Arkaitz Mucientes-Ruiz1, Sara Manrique-Arija1 and Natalia Mena Vázquez2, 1Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 2IBIMA, Málaga, Andalucia, Spain

Meeting: ACR Convergence 2024

Keywords: body composition, rheumatoid arthritis, TNF-blocking Antibody

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Previous studies have described alterations in fat and lean mass in patients with RA, but the effect of treatments on body composition remains unclear. The objectives of our study were to analyze the change in body composition in patients with RA after 6 months of a TNF inhibitor therapie and to identify the associated factors.

Methods: A controlled cross-sectional observational study of a prospective cohort over a 24-week period was performed. The study subjects were RA patients (ACR/EULAR 2010) with moderate-high mean inflammatory activity during the course of the disease who were selected to initiate first biologic therapy with a TNF inhibitor. All patients were assessed by a predefined questionnaire collecting clinical, analytical and body composition data by Dual-Energy X-ray absorptiometry (DXA) at the cut-off date, as well as after 24 weeks of biologic therapy.  The main variables were Fat Mass Index (FMI, Kg/m2), Lean Mass Index (LMI, Kg/m2) and total lean mass difference during the 6 months of treatment, expressed as total lean mass delta (kg). The inflammatory activity according to DAS28 and CRP was evaluated. Inflammatory mediators, adipocytokines levels and Insulin-like Growth Factor I (IGF-I) were also analyzed. Other included variables were comorbidities, anthropometric and clinical-analytical measurements, therapies and physical activity measured by the International Physical Activity Questionnaire (IPAQ) per Metabolic Equivalent of Task (METs). Statistical analysis included descriptive analysis, bivariate and one models of multivariate analysis.

Results: A total of 70 RA patients were included, most of them were female (81.4%) with a mean (SD) age of 56.2 (12.3) years. Table 1 shows the clinical and body composition characteristics at baseline and after 24 weeks of treatment with a TNF inhibitor. Table 2 shows the differences in analytical data, adipocytokines and interleukins. Patients reported clinical and analytical improvement in disease activity, with a significant decrease in inflammatory cytokines and increased resistin and adiponectin values. With respect to body composition, patients experienced a significant increase in LMI (p=0.016). However, regarding FMI, although a decrease was observed during the treatment period, these differences did not reach statistical significance (p=0.243). Significant inverse correlations were observed between LMI and level of adiponectin (p=0.019), IL-6 (p=0.001), CRP (p=0.046), IGF-1 (p=0.009) and ESR (p=0.010).  Furthermore, lean mass gain after 6 months of Anti-TNF treatment was significantly inversely correlated with disease duration (p=0.004), inflammatory activity by DAS28-CRP (p=0.023), CRP (p=0.012), as well as with physical function by HAQ (p=0.024). In the multivariate model, lean mass gain was negatively associated with inflammatory parameters, such as CRP (β = -0.440) and DAS28 (β = -0.333).

Conclusion: In RA patients, after 6 months of treatment with TNF inhibitors, a higher Lean Mass Index was observed.  The lower inflammatory activity after starting the biological therapy is associated with a higher lean mass gain in these patients. Nonetheless, no alterations in Fat Mass Index have been observed.

Supporting image 1

Supporting image 2


Disclosures: A. García-Studer: None; F. Ortiz-Márquez: None; P. Borregón-Garrido: None; A. Mucientes-Ruiz: None; S. Manrique-Arija: None; N. Mena Vázquez: None.

To cite this abstract in AMA style:

García-Studer A, Ortiz-Márquez F, Borregón-Garrido P, Mucientes-Ruiz A, Manrique-Arija S, Mena Vázquez N. Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/analysis-of-body-composition-in-patients-with-moderate-severe-rheumatoid-arthritis-treated-with-anti-tnf-drugs/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-body-composition-in-patients-with-moderate-severe-rheumatoid-arthritis-treated-with-anti-tnf-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology